- Home
- KG vs COYA Comparison
KG vs COYA Comparison
Compare KG & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KG | COYA |
|---|---|---|
| Founded | N/A | 2020 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.3M | 102.7M |
| IPO Year | 2025 | 2022 |
Fundamental Metrics
Financial Performance| Metric | KG | COYA |
|---|---|---|
| Price | $5.19 | $5.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.80 |
| AVG Volume (30 Days) | 37.7K | ★ 133.4K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1819.15 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,049,000.00 | $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $763.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 785.08 | 123.57 |
| 52 Week Low | $4.82 | $3.71 |
| 52 Week High | $27.55 | $7.75 |
Technical Indicators
Market Signals| Indicator | KG | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 36.33 | 54.14 |
| Support Level | N/A | $4.42 |
| Resistance Level | $12.02 | $5.17 |
| Average True Range (ATR) | 0.49 | 0.28 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 21.40 | 62.75 |
Price Performance
Historical ComparisonAbout KG Kestrel Group Ltd.
Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.